Related Experiment Video
Updated: Aug 5, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in
Samuel J P Malkin1, Saikrishna Kandalam2, Giorgia Guareschi3
1Ossian Health Economics and Communications, Basel, Switzerland.
Background:
Icodec is the first once-weekly basal insulin for type 2 diabetes (T2D), potentially improving quality of life through a reduced administration burden versus once-daily basal insulins. This study assessed the long-term cost-effectiveness of icodec versus glargine U100, degludec and a mix of once-daily basal insulins (degludec, glargine U100 and glargine U300) in insulin-naïve adults with T2D in Italy.
Methods:
Outcomes were projected over patient lifetimes (up to 60 years) using the PRIME T2D Model, discounted annually at 3.0%. Baseline characteristics and treatment effects were taken from ONWARDS 1, 3 and 5. Modelled patients received basal insulins for 4 years, before intensifying with the addition of bolus insulin. Treatment effects applied in the first year of the analysis and a utility benefit relating to once-weekly versus once-daily injection were maintained until intensification. Costs were expressed in 2024 euros (EUR) from the perspective of the Italian National Health Service.
Results:
Icodec was associated with improved quality-adjusted life expectancy of 0.16 quality-adjusted life years (QALYs) versus glargine U100 and degludec, and 0.26 QALYs versus the once-daily insulin mix. Benefits primarily resulted from the reduced injection frequency with icodec. Higher acquisition costs with icodec were partially offset by reduced use of consumables and modelled reductions in diabetes-related complications. Icodec was associated with incremental cost-effectiveness ratios of EUR 25 623, EUR 5438 and EUR 3940 per QALY gained versus glargine U100, degludec and the once-daily insulin mix, respectively.
Conclusions:
Icodec was projected to be cost-effective versus once-daily insulins for insulin-naïve people with T2D in Italy.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Type II Diabetes I: Introduction
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...